Non-invasive Goal-directed thErapy oN cIrcUlatory Shock

NARecruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

February 22, 2026

Study Completion Date

October 30, 2026

Conditions
Hemodynamics Instability
Interventions
DEVICE

Goal-Directed Therapy

"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."

Trial Locations (1)

05403-000

RECRUITING

Instituto do Coração, São Paulo

All Listed Sponsors
collaborator

Instituto Dante Pazzanese de Cardiologia

OTHER

lead

University of Sao Paulo

OTHER